Articles from: ash.confex.com
Mashup Score:11
ash.confex.comPaper: Phase III Study of Daratumumab/rhuph20 (nsc- 810307) + Lenalidomide or Lenalidomide As Post-Autologous Stem Cell Transplant Maintenance Therapyin Patients with Multiple Myeloma (mm) Using Minimal Residual Disease Todirect Therapy Duration (DRAMMATIC study): SWOG s1803 - 4 days
Mashup Score:11
Oral and Poster Abstracts 731. Clinical Autologous Transplantation: Results: Poster I Adult, Non-Biological, Therapies, Study Population, Clinically relevant Amrita Krishnan, MD1, Antje Hoering, PhD2,...
-
. @SWOG S1803 Ph3 Len +/- Daratumumab/rhuph20 as Post-ASCT Maintenance in Myeloma Using Minimal Residual Disease (#mmMRD) to direct Therapy Duration (DRAMMATIC) - @DoctorAKrishnan Hoering, @Phari Sexton, @Myeloma_Doc #ASH20 Abst 1515 https://t.co/IeLcOehWrr #NCT04071457 #mmsm https://t.co/IeLcOehWrr - view on twitter
Mashup Score:1
ash.confex.comOral and Poster Abstracts 731. Clinical Autologous Transplantation: Results: Poster I Adult, Non-Biological, Therapies, Study Population, Clinically relevant Amrita Krishnan, MD1, Antje Hoering, PhD2,...
-
. @SWOG S1803 Ph3 Len +/- Daratumumab/rhuph20 as Post-ASCT Maintenance in Myeloma Using Minimal Residual Disease (#mmMRD) to direct Therapy Duration (DRAMMATIC) - @DoctorAKrishnan Hoering, @Phari Sexton, @Myeloma_Doc #ASH20 Abst 1515 https://t.co/IeLcOeiugZ #NCT04071457 #mmsm https://t.co/IeLcOeiugZ - view on twitter
Mashup Score:44
ash.confex.comOral and Poster Abstracts Oral 615. Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies: New Approaches to Combination Chemotherapy and Venetoclax...
-
⚡️limiting VEN exposure to the concurrent days of AZA (7+7 ) had similar response rates like ven for 28d. ⚡️with this 7+7 scheme&ven at 50mg with posa is going to reduce the costs immensely in India with generics for posa and ven😊 https://t.co/UrpsuYU1tC #hemeonc #medtwitter https://t.co/UrpsuYU1tC - view on twitter
Mashup Score:11
ash.confex.comPaper: Phase III Study of Daratumumab/rhuph20 (nsc- 810307) + Lenalidomide or Lenalidomide As Post-Autologous Stem Cell Transplant Maintenance Therapyin Patients with Multiple Myeloma (mm) Using Minimal Residual Disease Todirect Therapy Duration (DRAMMATIC study): SWOG s1803 - 2 weeks
Mashup Score:11
Oral and Poster Abstracts 731. Clinical Autologous Transplantation: Results: Poster I Adult, Non-Biological, Therapies, Study Population, Clinically relevant Amrita Krishnan, MD1, Antje Hoering, PhD2,...
-
. @SWOG S1803 Ph3 Len +/- Daratumumab/rhuph20 as Post-ASCT Maintenance in Myeloma Using Minimal Residual Disease (#mmMRD) to direct Therapy Duration (DRAMMATIC) - @DoctorAKrishnan Hoering, @Phari Sexton, @Myeloma_Doc #ASH20 Abst 1515 https://t.co/IeLcOeiugZ #NCT04071457 #mmsm https://t.co/IeLcOeiugZ - view on twitter
Oral and Poster Abstracts 904. Outcomes Research—Non-Malignant Conditions: Poster I Coronaviruses, SARS-CoV-2/COVID-19, Adult, Diseases, Plasma Cell Disorders, Lymphoid Malignancies, Study Population, Myeloid Malignancies, Clinically...
-
Severity of Sars-Cov-2 Infection in Pts w/ Hematologic Malignancies: A COVID-19 & Cancer Consortium (#CCC19) Registry Analysis - @rubinstein_md et al. @mtmdphd @COVID19nCCC #ASH20 Abstract 1632 https://t.co/QiprV4WH2O #leusm #lymsm #mmsm #mpnsm #IDonc n=757 w/ #COVID19nCancer https://t.co/QiprV4WH2O - view on twitter
Mashup Score:4
ash.confex.comOral and Poster Abstracts 652. Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological: Poster II Research, Translational Research, Plasma Cell Disorders, Diseases, immunology,...
-
Dysregulated Humoral and Cellular Response to Sars-Cov-2 Vaccination in Patients with MGUS and SMM [Dec 11, 2022, 6-8p] Konishi et al. @IreneGhobrial Abs 3184 #ASH22 https://t.co/JURroguvYO #COVID19Vaccine #mmsm #IDonc #COVID19nCancer HT @CyclingDoctor cc @COVID19nCCC https://t.co/JURroguvYO - view on twitter
Oral and Poster Abstracts Oral 642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Drugs in Development and COVID-19 Research, clinical trials, Lymphoid Leukemias, CLL, Clinical...
-
RT @HemOncFellows: @NitinJainMD https://t.co/D89P6UMCPQ BRUIN trial https://t.co/D89P6UMCPQ - view on twitter
Mashup Score:11
ash.confex.comPaper: Phase III Study of Daratumumab/rhuph20 (nsc- 810307) + Lenalidomide or Lenalidomide As Post-Autologous Stem Cell Transplant Maintenance Therapyin Patients with Multiple Myeloma (mm) Using Minimal Residual Disease Todirect Therapy Duration (DRAMMATIC study): SWOG s1803 - 2 weeks
Mashup Score:11
Oral and Poster Abstracts 731. Clinical Autologous Transplantation: Results: Poster I Adult, Non-Biological, Therapies, Study Population, Clinically relevant Amrita Krishnan, MD1, Antje Hoering, PhD2,...
-
. @SWOG S1803 Ph3 Len +/- Daratumumab/rhuph20 as Post-ASCT Maintenance in Myeloma Using Minimal Residual Disease (#mmMRD) to direct Therapy Duration (DRAMMATIC) - @DoctorAKrishnan Hoering, @Phari Sexton, @Myeloma_Doc #ASH20 Abst 1515 https://t.co/IeLcOehWrr #NCT04071457 #mmsm https://t.co/IeLcOehWrr - view on twitter
Oral and Poster Abstracts 904. Outcomes Research—Non-Malignant Conditions: Poster I Coronaviruses, SARS-CoV-2/COVID-19, Adult, Diseases, Plasma Cell Disorders, Lymphoid Malignancies, Study Population, Myeloid Malignancies, Clinically...
-
Severity of Sars-Cov-2 Infection in Pts w/ Hematologic Malignancies: A COVID-19 & Cancer Consortium (#CCC19) Registry Analysis - @rubinstein_md et al. @mtmdphd @COVID19nCCC #ASH20 Abstract 1632 https://t.co/QiprV4W9dg #leusm #lymsm #mmsm #mpnsm #IDonc n=757 w/ #COVID19nCancer - view on twitter
Oral and Poster Abstracts Oral 642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Targeted Triplet Combinations and Richter’s Transformation Research, clinical trials, Lymphoid Leukemias, Biological...
@DrLizBrem @calliecoombsmd @ASkarbnik @DrMDavids Richters data: https://t.co/0jdXPPt8RZ The CLL patients haven’t been reported…? Not sure. - view on twitter